132 related articles for article (PubMed ID: 16505317)
1. Course of disability and respiratory function in untreated late-onset Pompe disease.
Hagemans ML; Hop WJ; Van Doorn PA; Reuser AJ; Van der Ploeg AT
Neurology; 2006 Feb; 66(4):581-3. PubMed ID: 16505317
[TBL] [Abstract][Full Text] [Related]
2. Disease severity in children and adults with Pompe disease related to age and disease duration.
Hagemans ML; Winkel LP; Hop WC; Reuser AJ; Van Doorn PA; Van der Ploeg AT
Neurology; 2005 Jun; 64(12):2139-41. PubMed ID: 15985590
[TBL] [Abstract][Full Text] [Related]
3. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease.
Van der Beek NA; Hagemans ML; Reuser AJ; Hop WC; Van der Ploeg AT; Van Doorn PA; Wokke JH
Neuromuscul Disord; 2009 Feb; 19(2):113-7. PubMed ID: 19084399
[TBL] [Abstract][Full Text] [Related]
4. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients.
Müller-Felber W; Horvath R; Gempel K; Podskarbi T; Shin Y; Pongratz D; Walter MC; Baethmann M; Schlotter-Weigel B; Lochmüller H; Schoser B
Neuromuscul Disord; 2007 Oct; 17(9-10):698-706. PubMed ID: 17643989
[TBL] [Abstract][Full Text] [Related]
5. Impact of late-onset Pompe disease on participation in daily life activities: evaluation of the Rotterdam Handicap Scale.
Hagemans ML; Laforêt P; Hop WJ; Merkies IS; Van Doorn PA; Reuser AJ; Van der Ploeg AT
Neuromuscul Disord; 2007 Jul; 17(7):537-43. PubMed ID: 17475490
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of late-onset Pompe disease: a prospective cohort study.
Wokke JH; Escolar DM; Pestronk A; Jaffe KM; Carter GT; van den Berg LH; Florence JM; Mayhew J; Skrinar A; Corzo D; Laforet P
Muscle Nerve; 2008 Oct; 38(4):1236-45. PubMed ID: 18816591
[TBL] [Abstract][Full Text] [Related]
7. [A retrospective study of six patients with late-onset Pompe disease].
Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients.
Hagemans ML; Winkel LP; Van Doorn PA; Hop WJ; Loonen MC; Reuser AJ; Van der Ploeg AT
Brain; 2005 Mar; 128(Pt 3):671-7. PubMed ID: 15659425
[TBL] [Abstract][Full Text] [Related]
9. Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities.
van der Beek NA; Soliman OI; van Capelle CI; Geleijnse ML; Vletter WB; Kroos MA; Reuser AJ; Frohn-Mulder IM; van Doorn PA; van der Ploeg AT
J Neurol Sci; 2008 Dec; 275(1-2):46-50. PubMed ID: 18757064
[TBL] [Abstract][Full Text] [Related]
10. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
Klinge L; Straub V; Neudorf U; Voit T
Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
[TBL] [Abstract][Full Text] [Related]
11. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations.
Palmer RE; Amartino HM; Niizawa G; Blanco M; Pomponio RJ; Chamoles NA
Neuromuscul Disord; 2007 Jan; 17(1):16-22. PubMed ID: 17056254
[TBL] [Abstract][Full Text] [Related]
12. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype.
Kroos MA; Pomponio RJ; Hagemans ML; Keulemans JL; Phipps M; DeRiso M; Palmer RE; Ausems MG; Van der Beek NA; Van Diggelen OP; Halley DJ; Van der Ploeg AT; Reuser AJ
Neurology; 2007 Jan; 68(2):110-5. PubMed ID: 17210890
[TBL] [Abstract][Full Text] [Related]
13. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study.
van Capelle CI; van der Beek NA; Hagemans ML; Arts WF; Hop WC; Lee P; Jaeken J; Frohn-Mulder IM; Merkus PJ; Corzo D; Puga AC; Reuser AJ; van der Ploeg AT
Neuromuscul Disord; 2010 Dec; 20(12):775-82. PubMed ID: 20817528
[TBL] [Abstract][Full Text] [Related]
14. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS
Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645
[TBL] [Abstract][Full Text] [Related]
15. Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.
van der Beek NA; van Capelle CI; van der Velden-van Etten KI; Hop WC; van den Berg B; Reuser AJ; van Doorn PA; van der Ploeg AT; Stam H
Mol Genet Metab; 2011; 104(1-2):129-36. PubMed ID: 21763167
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic criteria for late-onset (childhood and adult) Pompe disease.
American Association of Neuromuscular & Electrodiagnostic Medicine
Muscle Nerve; 2009 Jul; 40(1):149-60. PubMed ID: 19533647
[TBL] [Abstract][Full Text] [Related]
17. Development of a disease-specific disability instrument for Pompe disease.
Haley SM; Fragala MA; Aseltine R; Ni P; Skrinar AM
Pediatr Rehabil; 2003; 6(2):77-84. PubMed ID: 14534044
[TBL] [Abstract][Full Text] [Related]
18. Late-onset Pompe disease (LOPD): correlations between respiratory muscles CT and MRI features and pulmonary function.
Gaeta M; Barca E; Ruggeri P; Minutoli F; Rodolico C; Mazziotti S; Milardi D; Musumeci O; Toscano A
Mol Genet Metab; 2013 Nov; 110(3):290-6. PubMed ID: 23916420
[TBL] [Abstract][Full Text] [Related]
19. [Pompe's disease. Part I: pathogenesis and clinical features].
Illés Z; Trauninger A
Ideggyogy Sz; 2009 Jul; 62(7-8):231-43. PubMed ID: 19685701
[TBL] [Abstract][Full Text] [Related]
20. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
